VANDERBILT UNIVERSITY MEDICAL CENTER

Poseida Therapeutics’ P-BCMA-ALLO1, an allogeneic BCMA-directed CAR-T therapy, is being evaluated in a phase 1/1b clinical trial for relapsed/refractory multiple myeloma. The therapy, which does not require leukapheresis or manufacturing wait times, demonstrated a 91% overall response rate and no graft versus host disease in the enhanced lymphodepletion arm, as presented at the 21st International Myeloma Society Annual Meeting.

Dietary zinc deficiency exacerbates Acinetobacter baumannii lung infection, linked to increased IL-13 production, potentially treatable with anti-IL-13 antibodies.

A novel drug combination of pazopanib and bevacizumab showed a 54.9% objective response rate and 23.3 months median progression-free survival in metastatic kidney cancer patients, with 64 months median overall survival. Belzutifan, a HIF-2α inhibitor, had manageable safety profile with predominant severe toxicities of anemia and hypoxia. Sitravatinib could not be safely combined with the immunotherapy doublet of nivolumab and ipilimumab at standard doses due to immune-related adverse events.

Day 2 of the 2024 Huntington Study Group Conference featured talks on palliative care, clinical trial challenges, and updates from various drug development companies, emphasizing the importance of early intervention and the use of biomarkers in HD treatment.

Becker's 2024 list highlights hospitals & health systems excelling in oncology, recognized for advanced clinical trials & research. Notable institutions include AdventHealth, Allina Health, Arkansas Children's, Atlantic Health System, Banner MD Anderson Cancer Center, Baylor Scott & White Health, Boston Medical Center, Brown University Health, Children's Health, Children's Hospital Colorado, Children’s Hospital Los Angeles, Children’s Hospital of Orange County, Children's Hospital of Philadelphia, Children's Nebraska, ChristianaCare, City of Hope Comprehensive Cancer Center, Cleveland Clinic, Connecticut Children’s, Covenant Health, Dana-Farber Cancer Institute, Dartmouth Health, DeTar Hospital Cancer Center, Duke Health, El Paso Children's Hospital, Emory Healthcare, Endeavor Health, Fred Hutchinson Cancer Center/UW Medicine, Geisinger, Hackensack Meridian Health, Huntsman Cancer Institute at the University of Utah, Inova, Jefferson Health, Johns Hopkins, Jupiter Medical Center, Keck Medicine of USC, Laredo Medical Center, Lehigh Valley Health Network, MUSC Health, MaineHealth, Massachusetts General Hospital, Mayo Clinic, MedStar, MemorialCare, Memorial Sloan Kettering Cancer Center, Michigan Medicine, Mount Sinai Health System, Nebraska Medicine, New York-Presbyterian Hospital-Columbia and Cornell, Northwestern Medicine, Novant Health, OSF HealthCare, OU Health, Ochsner Health, Ohio State University Comprehensive Cancer Center, Oregon Health & Science University Hospital, Orlando Health, Penn Medicine, Providence Alaska Medical Center, Providence Cancer Institute of Oregon, Providence South Division Cancer Institute, Queen's Health System, RWJBarnabas Health and Rutgers Cancer Institute, Renown Health, Rochester Regional Health, Roper St. Francis Healthcare, Roswell Park Comprehensive Cancer Center, Sanford Health, Sarasota Memorial Health Care System, Scripps Health, St. Jude Children's Research Hospital, Stanford Medicine, Stanford Medicine Children's Health, Sutter Health, Swedish Cancer Institute, Sylvester Comprehensive Cancer Center at University of Miami, Tampa General Hospital, Texas Children's Hospital, UC Davis Health, UCLA Health, UCSF Health, UK HealthCare, UNM Health System, UVA Health, UW Health, UMass Memorial Health, University of Alabama Birmingham Hospital, University of Chicago Medical Center, University of Colorado Cancer Center-UCHealth University of Colorado Hospital, University Hospitals, University of Iowa Health Care, University of Kansas Health System, University of Texas MD Anderson Cancer Center, University of Vermont Health Network, Vanderbilt University Medical Center, Virtua Health, WVU Cancer Institute, WellSpan Health, Yale New Haven Health.

HTAN researchers analyzed thousands of cells to map cancer evolution, revealing gene regulation insights and tumor initiation as polyclonal processes, published in *Nature* journals.

Ursula Vogl discusses key prostate cancer trials from ESMO 2024: PATCH (transdermal estradiol vs. LHRH analogs in non-metastatic), ARANOTE (darolutamide in metastatic hormone-sensitive), and PEACE-3 (radium-223 plus enzalutamide in metastatic castration-resistant). Also covered are STAMPEDE (metformin's metabolic benefits) and SPLASH (lutetium PSMA-I&T therapy). Practical considerations include metformin's potential role despite lacking overall survival benefit and challenges in implementing radioligand therapy due to logistical, regulatory, and reimbursement issues.

A digital intervention combining text messages and a web-based dashboard, added to health behavior counseling, improved weight-for-length trajectories and reduced obesity incidence at 24 months in a diverse population, compared to counseling alone.

A preliminary study suggests TMS therapy may slow Alzheimer’s symptoms by 44%, targeting brain networks involved in memory. The experimental treatment, involving weekly sessions, showed little decline in daily living abilities and fewer side effects compared to current drug treatments.